# PARP Inhibition for Triple Negative Breast Cancer (ER-/PR-/HER2-)With BRCA1/2 Mutations

> **NCT01074970** · PHASE2 · COMPLETED · sponsor: **Hoosier Cancer Research Network** · enrollment: 135 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Cisplatin
- **DRUG:** Rucaparib
- **DRUG:** Cisplatin

## Key facts

- **NCT ID:** NCT01074970
- **Lead sponsor:** Hoosier Cancer Research Network
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-02
- **Primary completion:** 2018-12-15
- **Final completion:** 2018-12-15
- **Target enrollment:** 135 (ACTUAL)
- **Last updated:** 2024-09-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01074970

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01074970, "PARP Inhibition for Triple Negative Breast Cancer (ER-/PR-/HER2-)With BRCA1/2 Mutations". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01074970. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*